Intracoronary infusion of bone marrow mononuclear cells 2-3 weeks following a heart attack among patients with left ventricular dysfunction and who had a procedure such as balloon angioplasty or stent placement performed did not result in overall improvement in ventricular function after 6 months, according to a new study.

Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may ...

A team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in cancer patients after a bone marrow transplant.

Bone marrow-derived cells participate in the growth and spread of tumors of the breast, brain, lung, and stomach. To examine the role of BMDCs, researchers developed a mouse model that could be used to track the migration of these cells while tumors formed and expanded. Their results strongly suggest that ...

Through a clinical product called NurOwn, researchers in Israel are turning bone marrow stem cells into astrocyte-like cells which are responsible for the well-being of the brain's neurons. Trials for the technology, which has the potential to treat a broad range of neurodegenerative conditions, are now planned for Massachusetts General ...

All stem cells -- regardless of their source -- share the remarkable capability to replenish themselves by undergoing self-renewal. Yet, so far, efforts to grow and expand scarce hematopoietic (or blood-forming) stem cells in culture for therapeutic applications have been met with limited success.

A new study reports that a drug already approved by the U.S. Food and Drug Administration for use in patients undergoing a bone marrow transplant may also have promise for treating people who have a rare immune deficiency known as WHIM syndrome. People with the syndrome are more susceptible to ...

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years and 75 ...

Using a patient's own bone marrow stem cells to treat acute stroke is feasible and safe, according to the results of a ground-breaking Phase I trial.

Bone marrow transplantation with genetically modified cells may prolong the period of cancer-free survival, suggests a new study.

Researchers have reported that administration of granulocyte colony-stimulating factor, a drug that releases stem cells from the bone marrow into the blood, is unlikely to put healthy stem cell donors at risk for later development of abnormalities involving loss or gains of chromosomes that have been linked to hematologic disorders ...

Bone marrow transplant survival more than doubled in recent years for young, high-risk leukemia patients, with patients who lacked genetically matched donors recording the most significant gains.